14Aug 2024
Serum Biomarkers Predict Relapse in Crohn's Disease After Infliximab Withdrawal

Serum Biomarkers Predict Relapse in Crohn's Disease After Infliximab Withdrawal

This study validated the predictive ability of specific blood protein profiles for short-term and mid/long-term relapse in Crohn’s disease patients who stopped infliximab therapy. Comparing two cohorts, the study found that certain biomarker pairs outperformed existing models like CEASE, CRP, and faecal calprotectin in predicting relapse. These findings could guide more personalized decisions regarding infliximab withdrawal in Crohn’s disease management.

  • #gastroenterology

Like

Save

Share